Nondrug interventions for reducing SARS-CoV-2 transmission are frequently incompletely reported

Sanders, Sharon; Gibson, Elizabeth; Glasziou, Paul; Hoffmann, Tammy

doi:10.1016/j.jclinepi.2023.02.006

Cited by 1 publication

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, since the initiation of this study, work focussing on nonpharmacological interventions for reducing SARS‐CoV‐2 transmission has been published 20 . The degree to which nonpharmacological trials complied with TIDieR reporting standards, including Items 11 and 12, were comparable with our study findings.…”

Section: Discussionsupporting

confidence: 79%

“…Of note, since the initiation of this study, work focussing on nonpharmacological interventions for reducing SARS-CoV-2 transmission has been published. 20 The degree to which nonpharmacological trials complied with TIDieR reporting standards, including Items 11 and 12, were comparable with our study findings. We further note similar rates of compliance with TIDieR reporting guidelines in other studies beyond SARS-CoV-2, 18,19 including otolaryngology/head and neck clinical trials, 104 diabetes 105 and acute lymphocytic leukaemia.…”

Section: Intervention Adherencesupporting

confidence: 85%

“…Prior to this streamlined process, compliance with TIDieR guidelines has been shown to be suboptimal, including Items 11 and 12 17–19 . A recent study has shown poor compliance with TIDieR guidelines in trials focussed on nonpharmacological interventions for SARS‐CoV‐2, 20 in particular with Items 11 and 12, concluding such incomplete reporting hampers knowledge accumulation, the implementation of interventions and is an avoidable source of research waste. We know of no comparable assessments regarding pharmacological interventions in SARS‐CoV‐2.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical trials of pharmacological interventions for SARS‐CoV‐2 published in leading medical journals report adherence but not how it was assessed

Lee,

Otunla,

Brennan

et al. 2024

Brit J Clinical Pharma

View full text Add to dashboard Cite

BackgroundAdherence to pharmacological interventions in clinical trials is crucial for accurate identification of beneficial and adverse outcomes. The ways in which adherence to interventions should be reported in trial publications are described in the Template for Intervention Description and Replication (TIDieR), a 12‐item extension of the Consolidated Standards of Reporting Trials (CONSORT) reporting guidelines.ObjectiveTo assess compliance with TIDieR items 11 and 12 of randomised controlled trials (RCTs) of interventions in SARS‐CoV‐2 infection published in five selected journals during 2021.MethodsWe assessed pharmacological interventions for SARS‐CoV‐2 infection reported in RCTs published in 2021 in the Annals of Internal Medicine, The BMJ, JAMA, The Lancet, and The New England Journal of Medicine for compliance with TIDieR items addressing intervention adherence (items 11 and 12). We calculated proportional adherence for pharmacological and comparator interventions where available.ResultsWe found 75 eligible RCTs. 28 (37%) reported results of SARS‐CoV‐2 vaccinations. Compliance with items 11 and 12 could be assessed in 71 of these 75. Of the 71 RCTs, 37 (52%) reported how adherence was assessed (item 11) and 70 reported adherence rates (item 12). Only one of the 71 RCTs (1.4%, 0–7.6%) fully complied with TIDieR items 11and 12.ConclusionsHalf of RCTs of SARS‐CoV‐2 pharmacological interventions published in leading medical journals in 2021 complied with reporting of how adherence assessments were made and almost none complied with both TIDieR items 11 and 12. The implications for interpretation, application, and replication of findings based on these publications warrant consideration.

show abstract

Section: Discussionsupporting

confidence: 79%